Futurechem Co., Ltd. (220100)
Market Closed
10 Aug, 06:30
KRX SM KRX SM Primary ₩
9,120. 00
+350
+3.9909%
₩
723.67B Market Cap
- P/E Ratio
- Div Yield
39,991 Volume
- Eps
₩ 8,770
Previous Close Want to track 220100 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
220100 closed today higher at ₩9,120, an increase of 3.9909% from yesterday's close, completing a monthly decrease of -6.4615% or -₩630. Over the past 12 months, 220100 stock lost -70.5331%.
220100 is not paying dividends to its shareholders.
Futurechem Co., Ltd. has completed 4 stock splits, with the recent split occurring on Oct 24, 2022.
The company's stock is traded on one exchange.
Futurechem Co., Ltd. (220100) FAQ
What is the stock price today?
The current price is ₩9,120.00.
On which exchange is it traded?
Futurechem Co., Ltd. is listed on KRX SM.
What is its stock symbol?
The ticker symbol is 220100.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 723.67B.
Has Futurechem Co., Ltd. ever had a stock split?
Futurechem Co., Ltd. had 4 splits and the recent split was on Oct 24, 2022.
Futurechem Co., Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | - CEO | KRX SM Exchange | KR7220100002 ISIN |
| South Korea Country | 67 Employees | - Last Dividend | 2 Sep 2022 Last Split | - IPO Date |
Overview
Established in 1999 and based in Seoul, South Korea, FutureChem Co., Ltd, specializes in the production and sales of radiopharmaceuticals. The company is dedicated to developing advanced diagnostic and therapeutic products for various diseases, including Parkinson's, Alzheimer's, cancer, prostate cancer, atherosclerotic plaque, and brain tumors. FutureChem Co., Ltd is at the forefront of creating innovative solutions that meet the growing needs of the healthcare industry, particularly in the field of positron emission tomography (PET) radiopharmaceuticals.
Products and Services
- PDVUE: A PET radiopharmaceutical diagnostic medicine aimed at diagnosing Parkinson's disease, providing valuable insights into the condition and aiding in effective treatment planning.
- Alzavue: A dedicated diagnostic medicine for Alzheimer's disease, enabling the identification and evaluation of this neurodegenerative disease for better management and care of patients.
- [18F]FDG: A PET radiopharmaceutical primarily used in the cancer treatment process. It plays a crucial role in the detection, staging, and monitoring of various types of cancer, highlighting its versatility and importance in oncology.
- 18F-FC303: Currently in the pipeline, this diagnostic PET radiopharmaceutical is designed for the treatment of prostate cancer, indicating the company's commitment to expanding its solutions in oncology.
- 177Lu-FC705: Another innovative product in the pipeline aimed at treating prostate cancer, showcasing FutureChem Co., Ltd's dedication to combatting this common cancer affecting men globally.
- 18F-FMT: This product, targeted for the treatment of brain tumors, represents FutureChem Co., Ltd's efforts in addressing complex neuro-oncological challenges through advanced PET imaging technologies.
- 18F-FC505: A diagnostic tool in development for the treatment of atherosclerotic plaque. It underlines the company's venture into cardiovascular diseases, aiming to improve the diagnosis and treatment of heart-related conditions.
- 18F-FC211: Another Alzheimer's disease-targeting product, enriching the company's portfolio in neurodegenerative disease management and diagnosis, affirming its commitment to addressing the growing prevalence of Alzheimer's globally.
Contact Information
Address: PyeongHwa Building
Phone: 82 2 497 3114
Website: https://www.futurechem.co.kr
